Kush Parmar Sells 10,494 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 10,494 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $7.00, for a total value of $73,458.00. Following the sale, the director owned 2,836,098 shares in the company, valued at $19,852,686. The trade was a 0.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Kush Parmar also recently made the following trade(s):

• On Monday, August 10th, Kush Parmar sold 92,444 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.00, for a total transaction of $647,108.00.
• On Friday, August 7th, Kush Parmar sold 52,317 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.85, for a total transaction of $358,371.45.
• On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.85, for a total value of $11,768.30.
• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.93, for a total value of $795,259.08.

Entrada Therapeutics Stock Up 1.2%

NASDAQ TRDA traded up $0.08 during trading hours on Monday, hitting $6.95. The company’s stock had a trading volume of 411,770 shares, compared to its average volume of 464,800. The stock has a fifty day moving average of $6.86 and a 200 day moving average of $9.68. The firm has a market capitalization of $270.63 million, a P/E ratio of -1.76 and a beta of -0.26. Entrada Therapeutics, Inc. has a twelve month low of $4.93 and a twelve month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. On average, analysts predict that Entrada Therapeutics, Inc. will post -4.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming acquired a new stake in shares of Entrada Therapeutics during the second quarter worth $37,000. Russell Investments Group Ltd. raised its stake in Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new stake in Entrada Therapeutics in the 2nd quarter worth about $68,000. Jain Global LLC bought a new stake in Entrada Therapeutics in the 3rd quarter valued at about $69,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Entrada Therapeutics during the 2nd quarter worth approximately $72,000. 86.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TRDA has been the topic of several research analyst reports. Guggenheim dropped their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Monday, June 8th. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Roth Capital set a $10.00 price objective on shares of Entrada Therapeutics in a research note on Friday, May 8th. Finally, Weiss Ratings downgraded Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Entrada Therapeutics presently has an average rating of “Hold” and a consensus target price of $17.50.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.